OCT 22, 2020 7:00 AM PDT

Migraines: Dark Times and (Pharmaceutical) Rays of Hope

WRITTEN BY: Tara Fernandez


Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more prolonged and debilitating, encompassing a range of accompanying symptoms from throbbing pain and light sensitivity to nausea and vomiting. The pathophysiology of this condition is complex and identifying potential therapeutic targets has, for a long time, eluded neuroscientists. Among the challenges is that nobody knows what really causes migraines.

The current working theory is that the trigeminovascular system (a neural connection that innervates blood vessels in the head) is a major player. Recurrent activation and sensitization of this pathway alters the excitability of the brain, resulting in the hypersensitivity to light, sounds, and even smells. 

For the estimated 16 percent of the worldwide population that suffers from migraines, a silver lining has come in the form of a suite of migraine therapeutics that have recently entered the clinic. One of these is a migraine drug called erenumab (Aimovig) — a monoclonal antibody drug derived from natural immune systems. The antibody prevents both episodic as well as chronic migraines by blocking the activity of calcitonin gene-related peptide (CGRP), a potent peptide produced by neurons. Elevated levels of CGRP have been linked to a range of conditions including migraine, hypertension, and cardiac failure.

A recent study conducted by Australian scientists has highlighted the true potential of Erenumab at relieving severe migraine attacks in chronic sufferers. The study tracked migraine incidences in a cohort of almost 200 patients. After taking the drug, almost 60 percent of them had at least halved the number of migraines they experienced per month.

“These drugs represent a significant advance in migraine care, and with many patients describing them as ‘life-changing’, they bring new hope to many living with migraine disease,” said the study’s lead author Dr. Elspeth Hutton from Monash University.

Sources: Headache, AJMC, Nature.  


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 27, 2020
Immunology
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
OCT 27, 2020
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
A recent study published in Immunity details MIT scientists’ exploration of the underlying mechanisms of inflammat ...
NOV 05, 2020
Immunology
Awakening Ancient DNA to Kill Cancer
NOV 05, 2020
Awakening Ancient DNA to Kill Cancer
In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
DEC 15, 2020
Immunology
Yes, You Should Get Your Flu Vaccine.
DEC 15, 2020
Yes, You Should Get Your Flu Vaccine.
A recent study published in Science Translational Medicine has provided fresh insights on how our immune systems protect ...
DEC 28, 2020
Genetics & Genomics
Mapping Networks of Gene Expression in Cells
DEC 28, 2020
Mapping Networks of Gene Expression in Cells
Every cell contains our whole genome, but not all genes are turned on all the time; gene expression has to be very caref ...
JAN 28, 2021
Neuroscience
Immune Cells Destroy Synapses in Multiple Sclerosis
JAN 28, 2021
Immune Cells Destroy Synapses in Multiple Sclerosis
Researchers from Germany have found that Multiple sclerosis (MS)-associated inflammation in the cerebral cortex destroys ...
Loading Comments...